{"analyses":[{"ciLowerLimit":"0.278","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.450","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"Analysis is performed by randomization strata of HRD classification by CTA, best response, and penultimate platinum progression-free interval.","pValue":"<0.0001","paramType":"Cox Proportional Hazard","paramValue":"0.354","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.0","upperLimit":"19.1","value":"13.7"},{"groupId":"OG001","lowerLimit":"5.1","upperLimit":"5.5","value":"5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"To evaluate PFS by RECIST v1.1, as assessed by independent radiology review (IRR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG000","title":"Rucaparib 600 mg Tablets"},{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG001","title":"Placebo Tablets"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat: All patients randomized","reportingStatus":"POSTED","timeFrame":"Every 12 calendar weeks (within 7 days prior is permitted) after start of treatment until treatment discontinuation due to disease progression. Total follow-up was up to approximately 8.2 years.","title":"Disease Progression According to RECIST v1.1, as Assessed by Independent Radiology Review (IRR), or Death From Any Cause (irrPFS)","type":"SECONDARY","unitOfMeasure":"months"}